Document Type : Original article


1 Community Medicine Department, Faculty of Medicine. Mashhad University of Medical Sciences, Mashhad, Iran

2 Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran

4 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


Introduction: The breast cancer burden is still increasing, both in developing and developed countries. The present study was conducted to determine the survival rate of breast cancer based on tumor biological subtypes in patients referring to three referral oncology centers at Mashhad University of Medical Sciences, Mashhad, Iran.
Methods: The present population-based study was conducted at Imam Reza Hospital, Omid Hospital, and Reza Oncology Center, Mashhad University of Medical Sciences, Mashhad, Iran Demographic information, the status of biomarkers in immune-histochemical evaluation, clinical and pathological features of the tumor, type of therapy, recurrence, or death was recorded for each eligible patient.
Results: In total, 247 patients were included in the study. The mean age of patients was 48.8 ± 1.3 years. The mean time of survival was 2.64±0.13 years. In detail, the survival rate from the first year to the fifth year was reported as 100%, 96%, 91%, 90%, and 89%, respectively. The survival rate of the luminal B subtype was higher than other subtypes but the difference was not significant (P=0.7). Only in terms of metastasis, there was a significant difference between the alive and dead patients (P=0.0001).
Conclusion: Despite no significant relationship between biological markers, the breast cancer subtype, and its survival rate, the overall survival rate of the patients decreased lightly through five years. However, further studies are required to indicate more accurate data about the breast cancer survival rate in our region.


  1. Moodi Ghalibaf A. The Association Between Breast Cancer and Thyroid Function: From Birth to Death. Multidisciplinary Cancer Investigation. 2021;5(2):1-8.
  2. Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017. Journal of hematology & oncology. 2019;12(1):1-12.
  3. Besharat S, Motie MR, Besharat M, Roshandel G. Breast cancer risk factors in women of Golestan Province in Iran: a case-control study. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2011;13(6):46-51.
  4. Nafissi N, Khayamzadeh M, Zeinali Z, Pazooki D, Hosseini M, Akbari ME. Epidemiology and histopathology of breast cancer in Iran versus other Middle Eastern countries. Middle East Journal of Cancer. 2018;9(3):243-51.
  5. Masood S. Breast cancer subtypes: morphologic and biologic characterization. Women’s Health. 2016;12(1):103-19.
  6. Jones T, Neboori H, Wu H, Yang Q, Haffty BG, Evans S, et al. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer? Annals of surgical oncology. 2013;20:2866-72.
  7. Euceda LR, Haukaas TH, Giskeødegård GF, Vettukattil R, Engel J, Silwal-Pandit L, et al. Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy. Metabolomics. 2017;13:1-14.
  8. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011;305(6):569-75.
  9. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast cancer research. 2010;12(4):1-12.
  10. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Journal of the National Cancer Institute. 2006;98(9):599-609.
  11. Collins L, Marotti J, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast cancer research and treatment. 2012;131:1061-6.
  12. Bacchi L, Corpa M, Santos P, Bacchi C, Carvalho F. Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study. The Breast. 2010;19(2):137-41.
  13. Alvarado-Cabrero I, Valencia-Cedillo R, Barroso-Bravo S, editors. Breast Cancer (BC) in Mexican Women Younger Than Age 45 Years. A Clinicopathologic (CP) Study of 1,320 Cases. LABORATORY INVESTIGATION; 2011: NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA.
  14. Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, et al. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. The oncologist. 2014;19(10):1076-83.
  15. Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia‐Pacific Journal of Clinical Oncology. 2017;13(4):289-95.
  16. Badar F, Mahmood S, Yusuf MA, Sultan F. Epidemiology of cancers in Lahore, Pakistan, 2010–2012: a crosssectional study. BMJ open. 2016;6(6):e011828.
  17. Akbari M, Khayamzadeh M, Khoushnevis S, Nafisi N, Akbari A. Five and ten years survival in breast cancer patients mastectomies vs. breast conserving surgeries personal experience. 2008.
  18. Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in Iran, a national study. Iranian Red Crescent Medical Journal. 2012;14(12):798.
  19. Hashemi E, Montazeri A, Akbari E, Najafi M, Haghighat S, Kaviani A. Role of tumor markers in breast cancer recurrence. Journal of Guilan University of Medical Sciences. 2006;15(57):28-32.
  20. Moradi-Marjaneh M, Homaei-Shandiz F, Shamsian S, Mashhadi IE-Z, Hedayati-Moghadam M. Correlation of HER2/neu over expression, p53 protein accumulation and steroid receptor status with tumor characteristics: An Iranian study of breast cancer patients. Iranian Journal of Public Health. 2008;37(3):19-28.
  21. Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Rev Clin Med 2023; Vol 10 (No 4) Published by: Mashhad University of Medical Sciences ( Ebrahimi Gore H et al. Esmailnasab N. Breast cancer survival analysis based on immunohistochemistry subtypes (ER/PR/HER2): a retrospective cohort study. Archives of Iranian medicine. 2016;19(10):0-.
  22. Akbari M, Mozaffar M, Heidari A, Zirakzadeh H, Akbari A, Akbari M, et al. Recurrence and survival effect in breast conserving surgery: What are the predictive and/ or prognostic factors? International Journal of Cancer Management. 2011;4(2).
  23. Akbari ME, Akbari A, Nafissi N, Shormeij Z, Sayad S, Rasaf MR, et al. Prognostic factors of recurrence (early and late) and death in breast cancer patients in Iranian women. International Journal of Cancer Management. 2016;9(6).
  24. Ghalibaf AM. A triangle: COVID-19, breast cancer, and cancer therapy. Jundishapur Journal of Health Sciences. 2021;13(1).
  25. Ghalibaf AM, AkbariRad M, Karizmeh MA. Warning of the COVID-19 Novel Variant: Is the COVID-19 Omicron Variant a Real Danger for Cancer Patients or Not? Iranian Red Crescent Medical Journal. 2022;24(6).